加载中
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
常规交易时段
US$1.50
−US$0.09 · -5.66%
盘中时间采用ET。市场数据可能有所延迟。
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
日内区间
当前US$1.50
52周区间
当前US$1.50
盘中时间采用ET。市场数据可能有所延迟。
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
日内区间
当前US$1.50
52周区间
当前US$1.50
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM634.25万0.01%787.4亿 USD0.19%US$276.37-0.55%
Vanguard Extended Market ETFVXF339.66万0.00%954亿 USD0.05%US$231.91-0.69%
iShares Russell 2000 Value ETFIWN191.78万0.01%137.49亿 USD0.24%US$210.53-0.27%
Vanguard Russell 2000 ETFVTWO164.97万0.01%180亿 USD0.06%US$111.61-0.59%
iShares Micro-Cap ETFIWC77.18万0.06%13.17亿 USD0.60%US$179.75-1.05%
Simplify Propel Opportunities ETFSURI69.06万0.92%7606.44万 USD2.82%US$17.25650.00%
iShares Core S&P Total U.S. Stock Market ETFITOT61.12万0.00%980.88亿 USD0.03%US$169.12-0.19%
iShares Russell 2000 Growth ETFIWO39.03万0.00%139.17亿 USD0.24%US$350.82-0.82%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCSimplify Propel Opportunities ETFSURIiShares Core S&P Total U.S. Stock Market ETFITOTiShares Russell 2000 Growth ETFIWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
